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CD8 T cells contribute to protective immunity against Mycobacterium tuberculosis. In
humans, M. tuberculosis reactive CD8 T cells typically recognize peptides associated to
classical MHC class Ia molecules, but little information is available on CD8 T cells recog-
nizing M. tuberculosis Ags presented by nonclassical MHC class Ib molecules. We show
here that CD8 T cells from tuberculosis (TB) patients recognize HLA-E-binding M. tubercu-
losis peptides in a CD3/TCR αβ mediated and CD8-dependent manner, and represent an
additional type of effector cells playing a role in immune response to M. tuberculosis dur-
ing active infection. HLA-E-restricted recognition of M. tuberculosis peptides is detectable
by a significant enhanced ex vivo frequency of tetramer-specific circulating CD8 T cells
during active TB. These CD8 T cells produce type 2 cytokines upon antigenic in vitro stim-
ulation, help B cells for Ab production, and mediate limited TRAIL-dependent cytolytic
and microbicidal activity toward M. tuberculosis infected target cells. Our results, together
with the finding that HLA-E/M. tuberculosis peptide specific CD8 T cells are detected in
TB patients with or without HIV coinfection, suggest that this is a new human T-cell
population that participates in immune response in TB.
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Introduction
T-cell-mediated immune responses play a fundamental role in
fighting against Mycobacterium tuberculosis [1, 2]. Traditionally,
this response is mediated by Th1-type CD4 T cells secreting IFN-γ
[2, 3], but it has become clear that CD8 T cells also contribute
to protective immunity against M. tuberculosis [4] by the release
of Th1-type cytokines and cytotoxic and microbicidal molecules
that promote killing of M. tuberculosis infected macrophages and
restrict the growth of intracellular bacilli [2]. In humans, M.
tuberculosis reactive CD8 T cells recognize peptides associated to
classical HLA-A, HLA-B, and HLA-C class I (class Ia) molecules,
glycolipids associated to group 1 CD1 molecules [5, 6], and
mycobacterial Ag associated to MHC class I related molecule
(MR1) [7]. However, there is little information on the role that
these cells play during infection. In mice, the MHC class Ib
molecule H2-M3 binds formylated peptides derived fromM. tuber-
culosis and induces H2-M3-restricted CD8 T cells [8, 9] that are
protective against M. tuberculosis infection [10].
In humans, CD8 T cells restricted by class Ib molecules com-
prise the very large majority of the overall M. tuberculosis spe-
cific CD8 T-cell response [11] and CD8 T cells recognizing M.
tuberculosis Ags in the context of the class Ib molecule HLA-E
have been isolated from subjects with latent M. tuberculosis infec-
tion [12, 13]. However, the functions of this HLA-E-restricted
population, as well as its contribution to the host response to
M. tuberculosis during infection and disease, remain unknown.
HLA-E is the least polymorphic of all the HLA molecules
[14] with only two alleles in the Caucasian population,
which differ at one aa position located outside the peptide-
binding groove [15]. Physiologically, HLA-E binds non-
amer peptides derived from the signal sequence of other
HLA class I molecules [16, 17], and the HLA-E/peptide
complex in turn binds to CD94/NKG2A (inhibitory) and
CD94/NKG2C (activating) NK receptors [17–19]. However, HLA-
E also binds peptides derived from self-Ags [20, 21], tumors
[22], and pathogenic microorganisms [13, 23–26], including
M. tuberculosis [11–13], and presents them to CD8 T cells.
The lack of allelic variation in the peptide-binding groove may
be advantageous to design peptide-based vaccines against tuber-
culosis (TB). In fact, while the polymorphism of MHC class Ia
molecules is an obstacle for clinical application of these peptide-
based vaccination strategies, vaccines based on peptides presented
by HLA-E are suitable for the global heterogenic population.
In addition to its limited polymorphism, HLA-E offers another
potential advantage in relation to M. tuberculosis infection. As
opposed to HLA-A and HLA-B molecules, HLA-E is resistant to
HIV-nef-mediated downregulation [27, 28]. This is particularly
relevant in view of the high prevalence of HIV/M. tuberculosis
coinfection in countries such as South Africa where approximately
70% of TB patients are also HIV infected [29]. Thus, while HIV
might affect recognition ofM. tuberculosis coinfectedmacrophages
[30] by HLA class Ia molecules, HLA-E-dependent Ag presentation
and target-cell recognition are likely to be less or not affected
at all by HIV coinfection. Therefore, targeting M. tuberculosis
specific HLA-E-restricted responses by vaccination or immunother-
apy might be a novel and advantageous approach to combat TB.
In this article we have studied the epitope specificity, functional
attributes, and ex vivo frequencies of HLA-E-restricted CD8 T cells
specific for M. tuberculosis peptides in patients with active TB. We
show here that HLA-E-restricted CD8 T cells recognize M. tuber-
culosis peptides in a CD3/TCR αβ mediated and CD8-dependent
manner. Moreover, we provide evidence that during active TB dis-
ease, these cells produce type 2 (Tc2) cytokines, help B cells for Ab
production, and have very poor TRAIL-mediated cytolytic activity
and microbicidal potential. Finally, using HLA-E/M. tuberculosis
peptide tetramers we show that the frequency of such tetramer-
specific CD8 T cells declines after successful chemotherapy, indi-
cating that this novel human T-cell population participates in
immune response in TB.
Results
Identification of predicted HLA-E-binding
M. tuberculosis peptides
A recent study using a combination of several bioinformatic meth-
ods has led to the identification of 69 potential HLA-E-binding pep-
tides from the total M. tuberculosis H37Rv genome [13]. Despite
differences in their binding affinities to recombinant human
HLA-E, 79% peptides were recognized by at least one healthy
purified protein derivative (PPD) responder, in a CD8 T-cell-
proliferation assay [13]. Thus, and as found for other HLA class
I molecules as well [31], actual affinities determined in this bio-
chemical cell-free binding assay do not fully correlate with epitope
recognition by CD8 T cells. Therefore 18 peptides (Supporting
Information Table 1) were chosen to represent groups of six pep-
tides each that display high, intermediate, and low binding affinity
to HLA-E molecule in a cell-free assay, and these peptides were
screened for their capability to induce HLA-E cell surface expres-
sion and to elicit peptide-specific response of CD8 T cells from at
least 30% of patients with active TB disease.
To test the capacity of theM. tuberculosis peptides to bind HLA-
E, we performed a stabilization assay [17, 18, 32] in which TAP-
deficient RMA-S (TAP2 mutant Rauscher Murine Leukemia virus-
induced T cell lymphoma) cells transfected with HLA-E (RMA-
S/HLA-E) were cultured in the presence or absence of peptide at
37°C overnight and cell-surface expression of HLA-E analyzed by
flow cytometry.
In the absence of peptide, there was no evidence of HLA-
E expression (Supporting Information Fig. 1A). The canonical
VMAPRTLIL sequence (used as a positive control) identical to
that present in the leader sequence of most HLA-C alleles [33]
was able to stabilize HLA-E expression. Interestingly, culture with
M. tuberculosis peptide 44 resulted in the highest levels of HLA-E
expression. Peptide 34 also stabilized HLA-E cell surface expres-
sion although not to the extent of peptide 44. Coculture with pep-
tides 62 and 68 resulted in somewhat lower, but significant surface
levels of HLA-E expression compared to peptide 44, while peptide
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55 stabilized only poorly HLA-E molecules on RMA-S/HLA-E cells.
All other tested M. tuberculosis peptides failed to stabilize HLA
molecules on transfected RMA-S cells. Together the data demon-
strated that 5 of the 18 testedM. tuberculosis peptides (i.e. peptides
34, 44, 55, 62, and 68) were able to stabilize surface expression
of HLA-E, albeit to varying degrees.
In parallel with the analysis of HLA-E surface expression, the
18 M. tuberculosis peptides were tested for their capability to
induce proliferative responses of CD8 T cells from ten patients with
active TB. Peptide-induced CD8 T-cell responses were scored posi-
tive when exceeding 10% proliferation in the absence of peptide
(see Materials and Methods and [13]), in at least 30% of the
tested TB patients. According to these criteria, a total of 4 of the
18 tested peptides (i.e. peptides 34, 55, 62, and 68) were found
to elicit a CD8 T-cell response (Supporting Information Fig. 1B).
When HLA-E surface expression and CD8 T-cell response results
were compared, peptides 34, 62, and 68 were found capable of
stabilizing HLA-E surface expression and eliciting a CD8 T-cell
response; peptide 44 caused the highest HLA-E surface expression
but a very low CD8 T-cell response and conversely, peptide 55
induced relatively low HLA-E surface expression but significant
CD8 T-cell response.
Therefore, because HLA-E cell surface stabilization did not fully
correlate with the CD8 T-cell response, in subsequent experiments
we decided to use the five peptides that gave a positive result in
either assay.
HLA-E/M. tuberculosis peptide complexes are not
recognized by CD94/NKG2 receptors
The C-type lectin receptors CD94/NKG2A and CD94/NKG2C
specifically interact with HLA-E, resulting either in inhibition or
activation of NK-cell function [17–19]. Therefore we tested the
ability of M. tuberculosis peptides to affect target-cell lysis by NK-
cell clones expressing either CD94/NKG2A or CD94/NKG2C.
In order to address whether complexes of HLA-E and M. tuber-
culosis peptides inhibit lysis mediated by CD94/NKG2A+ NK cells,
the HLA class I negative K562 cells were transfected with HLA-E
(K562/HLA-E) and were incubated overnight at 37°C with either
M. tuberculosis peptides or the VMAPRTLIL peptide (used as con-
trol) and tested as targets in a 51Cr release assay (Fig. 1A).
As expected, K562/HLA-E cells were efficiently killed by
CD94/NKG2A+ NK-cell clones (e.g. 26.3 and 7.1 clones) and
incubation of target cells with the VMAPRTLIL reference peptide
was able to protect them from killing (Fig. 1A). Preincubation
of NK cells with anti-CD94 mAb reversed inhibition of cytolysis,
demonstrating recognition of HLA-E/VMAPRTLIL complexes by
the inhibitory CD94/NKG2A receptor (Fig. 1A). In contrast, all
tested M. tuberculosis peptides failed to protect K562/HLA-E cells
from killing by CD94/NKG2A+ NK-cell clones and cytotoxicity was
not (or was only minimally) altered by the presence of anti-CD94
mAb (Fig. 1A).
We then investigated whether HLA-E molecules loaded with
M. tuberculosis peptides are recognized by NK-cell clones express-
ing a functional activatory CD94/NKG2C receptor. To this end,
Figure 1. M. tuberculosis derived peptides are not recognized by
NKG2A+ by NKG2C+ NK-cell clones. (A) 51Cr-labeled K562/HLA-E cells
were incubated either alone (no peptide) or in the presence of the
VMAPRTLIL peptide (Control peptide) or the indicated M. tuberculosis
peptides and were tested for susceptibility to lysis by NKG2A+ NK-cell
clones (26.3 and 7.1) at different E:T ratios in the absence (black) or pres-
ence (white) of anti-CD94 mAb Y9 (IgM). (B) 51Cr-labeled RMA-S/HLA-E
cells were incubated as in (A) and were tested for susceptibility to lysis
by NKG2C+ NK-cell clones (41.3 and 21.6) at different E:T ratios in the
absence (black) or presence (white) of anti-CD94 mAb Y9 (IgM). (A and
B) Data are from one experiment representative of five independent
experiments, each performed in duplicate.
RMA-S/HLA-E cells incubated with either M. tuberculosis peptides
or the VMAPRTLFL reference peptide (used as control) were tested
as targets in a 51Cr release assay with the CD94/NKG2C+ NK-
cell clones 41.3 and 21.6 as effectors. VMAPRTLFL-loaded RMA-
S/HLA-E cells were killed more efficiently than control target cells
(i.e. unpulsed RMA-S/HLA-E) and lysis of VMAPRTLFL-pulsed
RMA-S/HLA-E cells was inhibited on mAb-mediated masking of
CD94 (Fig. 1B). In contrast, incubation of RMA-S/HLA-E cells
with the M. tuberculosis peptides had no impact on target-cell
recognition by CD94/NKG2C+ NK-cell clones and the presence of
anti-CD94 mAb did not alter target-cell lysis.
Taken together, these results indicate that complexes of HLA-E
andM. tuberculosis peptides do not engage inhibitory or activatory
CD94/NKG2 receptors.
Recognition of HLA-E/M. tuberculosis peptides requires
the TCR αβ and is CD8 dependent
To further investigate the Ag-recognition requirements of the
HLA-E-binding M. tuberculosis peptide-responding T cells in
more detail, we examined responses in three TB patients against
five peptides using peptide-specific polyclonal CD8 T-cell lines
generated by peptide stimulation of PBMCs. Donors were
selected on the grounds that (i) there was peptide-dependent
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Figure 2. Peptide specificity and
recognition requirements of M. tuber-
culosis specific HLA-E-restricted CD8
T-cell lines. (A) CD8 T-cell lines
(5 × 104) were cultured for 24 h
with an equal number of irradiated
K562/HLA-E cells pulsed or unpulsed
with peptides, and TNF-α production
assessed by ELISA. (B) CD8 T cells
were stimulates as in (A) but in the
presence of the indicated blocking
mAbs. After 24 h, the supernatants
were collected and TNF-α levels were
assessed by ELISA. Data are shown as
mean± SD (n= 3) and are pooled from
two independent experiments, each
performed in triplicate. *p < 0.001
when compared to control, as calcu-
lated by the Mann–Whitney U test.
CD8 T-cell-proliferative response in that specific donor and
(ii) sufficient PBMCs were available. Phenotype characteristics
of the lines are summarized in Supporting Information Table
2 and representative data with the E#68-1 cell line are shown
in Supporting Information Figure 2. T-cell lines displayed a
CD3+CD8+TCRαβ+ phenotype and did not express either CD56
or CD16. CD94 was expressed by 8 of the 15 lines on an average
of 22% of the cells. Similarly, the activatory NKG2C receptor was
expressed by less than 15% of the cells in only three lines, and the
inhibitory NKG2A receptor was expressed by 2 of the 15 tested
cell lines, on less than 20% of their cells. Three lines expressed
granzyme B and TRAIL on the vast majority of cells, but none
expressed perforin and granulysin.
All the tested CD8 T-cell lines exhibited fine Ag specificity and
strict HLA-E dependence, as demonstrated by their capability to
produce TNF-α only when stimulated by K562/HLA-E cells loaded
with the specific peptide. Figure 2A shows primary data obtained
with five representative T-cell lines. In no case TNF-α produc-
tion was detected by stimulation of CD8 T-cell lines with peptide-
pulsed K562 cells (data not shown).
To assess the contribution of the TCR or NK receptors and
HLA-E interaction to target-cell recognition, we performed mAb
blocking experiments, in which peptide-loaded K562/HLA-E cells
were used to stimulate TNF-α production by CD8 T-cell lines. As
shown in Figure 2B, significant inhibition of TNF-α production
was observed in the presence of blocking mAbs to CD3, TCR αβ,
CD8, pan-HLA class I, or HLA-E molecules. Blocking mAbs spe-
cific for NKG2D, NKG2C, CD94, or HLA-A/B/C molecules had no
inhibitory effect on this process, while capable to inhibit killing
of target cells by NK or HLA-A*0201-restricted CD8 T-cell clones
(Supporting Information Fig. 3).
Together, these data unveil the requirement for TCR αβ medi-
ated and CD8-dependent recognition of HLA-E-binding M. tuber-
culosis peptides.
Functional properties of HLA-E-restricted and
M. tuberculosis specific CD8 T cells
To assess the cytokine profile of HLA-E-restricted and M. tubercu-
losis specific CD8 T cells, we stimulated T-cell lines with specific
peptides and tested cytokine production by ELISA in 24-h super-
natants. All 15 CD8 T-cell lines produced TNF-α and 2 lines also
produced low yet detectable levels of IL-2 (Fig. 3A). Additionally,
9 of the 15 tested cell lines produced significantly IL-4 and IL-13,
either alone or in combination with, IL-5, IL-10, and/or TGF-β,
while we failed to detect production of IFN-γ, IL-17, and IL-22.
Cytokine production was strictly peptide specific as no significant
cytokine production was detected with T-cell lines stimulated by
peptides different than those used to generate the line. Figure
3B shows representative specificity results with two different CD8
T cell lines, E#34-1 and E#68-3.
Even if the generation of HLA-E-restricted CD8 T-cell lines
was carried out under neutral culture conditions (i.e. with IL-2
and in the absence of polarizing cytokines), we cannot exclude
that their cytokine pattern may be biased by prolonged in vitro
stimulation. Therefore, we decided to define the cytokine pro-
duced by CD8 T cells directly ex vivo upon stimulation of PBMCs
from seven patients with active TB disease with M. tuberculosis
peptides. Intracellular cytokine staining confirmed the dominant
IL-4 and IL-13 cytokine production by the CD8+ T cells and the
lack of IFN-γ secretion. Primary data from seven TB patients (with
PBMCs) stimulatedwith peptide 68 are shown in Supporting Infor-
mation Figure 4.
Thus, and differently from CD8 T cells recognizing M. tuber-
culosis peptides in the context of HLA-class Ia molecules [31, 34–
37], CD8 T cells recognizingM. tuberculosis peptides presented by
HLA-E have an unorthodox Tc2-like, multifunctional phenotype.
Therefore, we looked into whether these cells support B cells to
secrete Ig. To that end, CD8 T-cell lines were cultured in the
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Figure 3. Cytokine production and
induction of IgG synthesis byM. tuber-
culosis specificHLA-E-restricted CD8T-
cell lines. (A and B) CD8 T-cell lines
were stimulated with specific peptide
as described above for 24 h, the super-
natants were collected and cytokine
levels were assessed by ELISA. Data
are mean of three independent exper-
iments, each performed in triplicate
(SD < 10% of the means). (B) Data
shown are from two representative
CD8 T-cell lines. (C) Tonsillar B cells
were cultured for 10 days either alone
(black-filled columns) or in the pres-
ence of HLA-E-restricted CD8 T-cell
lines (gray-filled columns) or normal
CD8 T cells sorted from PBMCs (white
columns). IgG and IgM concentra-
tions in the culture supernatants were
determined by ELISA. A representative
example with three different CD8 T-
cell lines is shown. Data are shown
as mean + SD (n = 3) and are repre-
sentative of four independent experi-
ments *p < 0.001 when compared to B
cells cultured alone, as calculated by
the Mann–Whitney U test.
presence of sorted tonsillar CD19+ B cells and Ab production
assessed by ELISA. B cells produced comparable low amounts of
IgG and IgM when cultured for 10 days without CD8 T-cell lines.
In contrast, coculture of B cells with 9 of the 15 HLA-E-restricted
CD8 T-cell lines resulted in a significant increase in the produc-
tion of IgG and IgM. As a control, coculture of tonsillar B cells with
sorted CD8+ T cells isolated from the PBMCs of healthy donors
did not increase significantly Ab production. Figure 3C shows rep-
resentative experiments with three different HLA-E-restricted CD8
T-cell lines. These data indicate that CD8 T cells recognizing M.
tuberculosis peptides presented by HLA-E supply B cells with the
signals required for Ig production.
With regard to their potential ability to develop cytotoxic
responses, only 3 of the 15 tested CD8 T-cell lines were equipped
with specific lytic activity, E#44-1, E#55-2, and E#68-1 (Fig. 4A),
as shown by their ability to kill K562/HLA-E cells pulsed with the
specific peptide (Fig. 4B). Most notably, the three cytotoxic CD8
T-cell lines were also able to kill K562/HLA-E or human mono-
cytic THP-1 target-cell lines infected with virulent M. tuberculosis
(Fig. 4C), indicating that the HLA-E-restricted peptides they rec-
ognize are generated during natural infection. However, HLA-
E-restricted CD8 T-cell lines only minimally reduced the viabil-
ity of intracellular M. tuberculosis (Fig. 4D) in K562 and THP-1
target-cell lines. As a control, an HLA-A*0201-restricted CD8 T-
cell clone specific for M. tuberculosis Ag 16-kDa120–128 was fully
able to reduce the viability of intracellular M. tuberculosis.
To further elucidate the mechanisms responsible for killing
of CD8 T cells recognizing M. tuberculosis peptides in the con-
text of HLA-E, we individually inhibited the granule exocytosis-,
TRAIL-, TNF-α-, and FasL-mediated (FasL is Fas ligand) pathways.
In agreement with flow cytometry data (Supporting Information
Table 2), treatment of CD8 T cells with concanamycin A (CMA),
an inhibitor of vacuolar type H+-ATPase that blocks perforin-
based cytotoxic activity, had no effect on killing of peptide-treated
K562/HLA-E-cell targets (Supporting Information Fig. 5), thus
excluding involvement of the perforin pathway. Addition of mAbs
against TRAIL-R1 and TRAIL-R2 caused 82–86% inhibition of
target-cell killing, indicating that TRAIL played a major role in the
killing activity of HLA-E-restricted CD8 T-cell lines. Finally, mAbs
to FasL and TNF-α failed to significantly inhibit the cytotoxicity of
all three tested HLA-E-restricted CD8 T-cell lines.
Validation of HLA-E-restricted and M. tuberculosis
specific CD8 T cells using tetramers
Using HLA-E/peptide tetramers for four HLA-E-binding peptides,
direct ex vivo recognition by TB patients CD8 T cells was demon-
strated for all four M. tuberculosis epitopes (Fig. 5A and B). In
all tested individuals, specificity of tetramer staining was con-
firmed by the absence of staining among PBMCs from ten nor-
mal, uninfected donors using the same M. tuberculosis tetramers
(Fig. 5A).
Although there was considerable variability in the proportions
of CD8 T cells that bound to single tetramers, the ex vivo fre-
quency of tetramer-specific CD8 T cells was higher in TB patients
than in latent tuberculosis infection (LTBI) subjects and this differ-
ence attained statistical significance with all epitopes. Significant
differences in frequencies of epitope-specific CD8 T cells were
observed in TB patients before and after chemotherapy: in all
instances mean frequencies of epitope-specific CD8 T cells signifi-
cantly decreased after therapy and differences attained statistical
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Figure 4. Cytotoxic activity of M. tuberculosis specific HLA-E-restricted CD8 T-cell lines. (A) Cytotoxic activity of 15 different HLA-E/M. tuberculosis
peptide specific CD8 T-cell lines toward peptide-pulsed or unpulsed K562/HLA-E target cells. (B) Peptide specificity in the killing activity of three
different CD8 T-cell lines toward K562/HLA-E target-cell lines pulsed with the specific or irrelevant peptides. (C, D) Three different HLA-E/M.
tuberculosis peptide specific CD8 T cell lines were coincubated with uninfected or M. tuberculosis H37Rv infected K562, K562/HLA-E, and THP-1 cell
line target cells. Cytotoxic activity toward targets was assessed after 6-h coculture, whileM. tuberculosis CFUs were estimated after 20-h coculture.
The human HLA-A*0201-restricted CD8 T-cell clone specific for M. tuberculosis Ag 16-kDa120-128 [52] was used as a positive control. (A–D) Bars
represent mean ± SD (n = 3) and data are from one experiment representative of five independent experiments. (A) *p < 0.005 and **p < 0.01 when
compared to unpulsed K562/HLA-E target cells, as calculated by the Mann–Whitney U test. (B) *p < 0.001 when compared to unpulsed target cells.
(C) *p < 0.002 when compared to uninfected K562 and THP-1 target cells, as calculated by the Mann–Whitney U test. (D) *p < 0.005 and **p < 0.01
when compared to control, as calculated by the Mann–Whitney U test.
significance with most of the studied epitopes (i.e. peptides 44, 55,
and 62). Finally, and most notably, the highest mean frequency
of tetramer-specific CD8 T cells was found in three TB patients
who were coinfected by HIV, which declined after antitubercu-
lous therapy as well. Figure 5A shows FACS analysis of the CD8+
tetramer+ T cells of one individual from any tested group and
Figure 5B shows cumulative data from 24 patients with active TB
disease before and after therapy, and 11 LTBI individuals.
As five TB patients were typed as HLA-A*0201+ and we had
available HLA-A*0201/M. tuberculosis peptide tetramers, we fol-
lowed up the CD8 T-cell response to HLA-A*0201- and HLA-E-
restricted epitopes in the same patients during therapy. As shown
in Figure 6, the frequencies of HLA-E-epitope-restricted CD8
T cells significantly decreased after 6-month therapy, while mean
frequencies of HLA-A*0201-restricted, epitope-specific (ESAT-6,
Rv1490, Ag85, and 16-kDa Ags) CD8 T cells increased after ther-
apy.
Thus, the opposite trend of HLA-E- and HLA-A*0201-restricted
responses strongly suggests these two CD8 T-cell populations
may play different roles during M. tuberculosis infection and
disease.
Discussion
Within recent years, it has become clear that HLA-E can present
peptides from several bacteria and viruses to CD8+ T cells in
a manner comparable to peptides presented by classical MHC
class I molecules [14, 24, 38–42]. Indeed, HLA-E-restricted CD8+
T-cell recognition of peptides from pathogens may be an impor-
tant mechanism of immune regulation during infections, as was
first demonstrated for M. tuberculosis [12, 13]. HLA-E is enriched
in the M. tuberculosis phagosome compared to regular HLA class I
molecules [43], suggesting that HLA-E may have unique functions
in presenting phagosomal Ags. Because M. tuberculosis resides in
immature phagosome, the probability that some peptides derived
from M. tuberculosis could be presented to CD8 T cells during
active infection in association with HLA-E molecules is intriguing.
Accordingly, careful examination of HLA-E-restricted CD8+ T-cell
responses to peptides fromM. tuberculosis found such responses to
a number of these peptides [13]. Therefore in our study, we were
interested in examining whether TB patients had a detectable
CD8+ T-cell response to peptides derived from M. tuberculosis,
which have been shown capable to bind to HLA-E.
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Figure 5. Ex vivo analysis of the frequencies of HLA-E/M. tuberculosis peptide tetramer+ CD8 T cells. (A) Dot plot analysis of HLA-E/peptide
tetramer+ CD8+ T-cell populations of one representative healthy tuberculin-negative subject, LTBI subject, and TB patient with active or cured TB
disease, with or without HIV coinfection. Shown in the upper left of each FACS plot are the percentages of tetramer+ CD8+ T cells, for all four tested
M. tuberculosis peptide/HLA-E tetramers. Data shown are representative of three independent experiments. (B) Cumulative data on the frequencies
of the tetramer-specific CD8 T cells in peripheral blood of 11 LTBI subjects (black columns) and 24 TB patients with active (gray columns) or cured
(white columns) TB disease. Data are shown as mean + SD (n = 3) and are representative of three independent experiments.
*p < 0.01 and **p < 0.02 when compared to patients with active TB disease, as calculated by the Mann–Whitney U test.
In this article, using a selected pool of M. tuberculosis peptides
capable to stabilize the HLA-E molecule on the surface of trans-
fected cells and to induce proliferation of CD8 T cells in PBMCs
from at least 30% TB patients, we provide direct evidence that
during active TB HLA-E-restricted CD8 T cells can recognize such
M. tuberculosis peptides, thus representing an additional type of
effector cells playing a role in immune response to active infection
with M. tuberculosis.
Usually, HLA-E/peptide complexes may serve as a ligand for
CD94/NKG2A or C, which are NK-cell-inhibitory and NK-cell-
activating receptors, respectively [17, 18]. CD94/NKG2A appears
to bind ligand with higher affinity, which has led to the notion
that HLA-E/peptide complexes may protect target cells from
NK-cell-mediated killing [44, 45]. Conversely, engagement of
CD94/NKG2C promotes NK-cell killing [44, 45]. In theory, presen-
tation of the M. tuberculosis derived peptides by HLA-E molecule
may have similar consequences. However, and in contrast to the
HLA-E/self-peptide complexes, we did not find recognition of HLA-
E/M. tuberculosis peptide complexes by NK-cell clones selectively
expressing inhibitory (NKG2A) or activatory (NKG2C) receptors.
Thus, we propose that HLA-E/M. tuberculosis peptide complexes
may have very low or even impaired affinity for CD94/NKG2A or
C receptors. Moreover, using T-cell lines generated from PBMCs
of TB patients by long-term peptide stimulation in vitro, we
Figure 6. Comparison of the frequencies of HLA-A*0201/M. tuberculosis peptide and HLA-E/M. tuberculosis peptide tetramer+ CD8 T cells during
antimycobacterial therapy. Frequency of (A) HLA-E/M. tuberculosis and (B) HLA-A*0201/M. tuberculosis tetramer+ CD8+ T cells in PBMCs of five
HLA-A*0201-positive TB patients (patients) before (TB0) chemotherapy and 4 (TB4) and 6 (TB6) months after chemotherapy. Data shown are
representative of three independent experiments.
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demonstrate that CD8+ T cells recognize HLA-E/M. tuberculosis
peptide complexes. Importantly, HLA-E/M. tuberculosis peptide
complexes are recognized differently from HLA-E/self-peptides:
whereas the latter are predominantly recognized by CD8-negative
cells (subset of NK cells) in a CD94-dependent manner, HLA-E
/M. tuberculosis peptides are specifically recognized by CD8+
T cells in a CD3/TCR αβ mediated and CD8-dependent manner.
Finally, HLA-E/M. tuberculosis peptide tetramers did not bind to
CD8-negative cells, although this subset is expected to contain
an NK-cell subset expressing CD94/NKG2. Altogether, the above-
reported results strongly indicate that HLA-E-restricted CD8
T cells recognize M. tuberculosis peptides differently than NK
cells but in a similar manner as HLA-class I-restricted CD8
T cells.
Human CD8+ T-cell lines derived from TB patients efficiently
recognize HLA-E-bindingM. tuberculosis peptides, resulting in cell
proliferation, but the responding cells had very poor cytotoxic
activity to HLA-E-expressing cells (K562 and THP-1). This was
initially suspected by the lack of expression of perforin and gran-
ulysin, and confirmed by the finding that only 3 of the 15 tested
HLA-E-restricted M. tuberculosis specific CD8 T-cell lines lysed
these target cells. Nonetheless, killing of targets occurred in a
peptide-specific and HLA-E-dependent fashion, strongly suggest-
ing peptide/HLA-E cognate recognition via the TCR. Moreover,
these epitopes are also likely recognized during natural infec-
tion, since live M. tuberculosis infected K562/HLA-E and THP-1
cell lines were lysed by HLA-E/peptide-specific effector CD8
T cells. However, despite their capability to kill peptide-pulsed and
M. tuberculosis infected target cells, all three HLA-E-restricted CD8
T-cell lines caused only minimal, if any inhibition of M. tuberculo-
sis outgrowth from these infected human cell lines, indicating that
they are equipped with cytolytic potential but lack microbicidal
activities. The latter finding could indicate that HLA-E-restricted
M. tuberculosis peptide specific CD8 T cells during active TB have
an impaired ability to inhibit M. tuberculosis outgrowth, since in
another study (submitted) we find that T-cell clones from latently
infected individuals were able to inhibitM. tuberculosis outgrowth
from infected primary human macrophages. Alternatively, exper-
imental differences (e.g. the use of cell lines here versus primary
cells in our other study) might account for this seeming difference.
In any case, the lack of correlation between target-cell apoptosis
and antimicrobial activity by M. tuberculosis specific CD8 T cells
is not surprising and was first reported by Modlin and co-workers
[5].
In addition to their poor cytolytic capacity, HLA-E/peptide-
reactive CD8 T-cell lines from TB patients also had an unusual
Tc2-type pattern of cytokine production: they secreted TNF-α and
two lines also produced low, yet detectable, levels of IL-2. How-
ever, and surprisingly, 9 of the 15 tested cell lines secreted IL-4
and IL-13, either alone or in combination with IL-5, IL-10, and/or
TGF-β, while very low or no production of IFN-γ, IL-17, and IL-22
was detected. The cytokine production profile of HLA-E-restricted
CD8 T-cell lines was confirmed by intracellular staining of freshly
isolated CD8 T cells stimulated withM. tuberculosis peptides. Thus,
HLA-E/M. tuberculosis peptide specific CD8 T cells more closely
resemble Tc2 T cells and accordingly they are capable to provide
help to B lymphocytes for Ab production. Moreover, the finding
that some CD8 T-cell lines also secrete TGF-β suggests that a frac-
tion of these cells might play regulatory activities, as shown by
previous studies in autoimmune disease models [46] and response
to microorganisms [47], including TB [13].
Overall, data reported here differ from previously described
HLA-E-restricted, TB-specific CD8 T cells that produce IFN-γ and
are cytolytic [12, 13]. However, we would like to point that in
the Heinzel paper [12] only two HLA-E-restricted and TB-specific
CD8 T-cell clones were studied, both derived from one healthy
LTBI subject, and cytotoxic activity of the clones was not assessed.
Similarly, in the Joosten paper [13] only two of four tested HLA-E-
restricted CD8 T-cell lines produced IFN-γ and all four lines killed
BCG-infected targets but also exerted TGF-β-mediated suppres-
sive activities. None of the studies investigated the microbicidal
properties of HLA-E-restricted CD8 T cells. In our studies, CD8
T-cell lines were generated from patients with active TB and a
total of 15 CD8 T-cell lines were tested. Moreover, the cytokine
producing profile of the T-cell lines was also evident when CD8
T cells were stimulated ex vivo with HLA-E-bindingM. tuberculosis
peptides.
Using HLA-E/peptide tetramers for four recognized HLA-E-
binding M. tuberculosis derived peptides, direct ex vivo recogni-
tion by TB patients’ CD8 T cells was demonstrated for all four epi-
topes and frequencies of peptide/tetramers in TB patients declined
6 months after the antimycobacterial therapy. One may speculate
that expansion of HLA-E-restricted andM. tuberculosis specific CD8
T cells during active TB disease might be the consequence of active
replication of M. tuberculosis residing in immature phagosomes.
Since HLA-E is enriched within the M. tuberculosis phagosome, as
compared to HLA class I molecules, the probability that endoge-
nous peptides derived from M. tuberculosis could be presented to
CD8 T cells in association with HLA-E molecules is very high dur-
ing active TB disease but diminishes after successful therapy. In
this case, the frequency of HLA-E-restricted/M. tuberculosis pep-
tide specific CD8 T cells may be a TB-specific biomarker of bacterial
load during active infection, which is also rapidly regulated during
successful chemotherapy.
In conclusion, our studies have identified CD8 T cells from
TB patients, which recognize M. tuberculosis derived peptides
presented by HLA-E molecules, produce type 2 cytokines upon
antigenic in vitro stimulation, mediate B-cell help for Ab pro-
duction, and have very limited TRAIL-dependent cytolytic activity
and microbicidal potential toward M. tuberculosis infected human
cell lines expressing HLA-E. These data, together with the finding
that the frequency of HLA-E/M. tuberculosis peptide specific CD8
T cells declines after successful chemotherapy in TB patients with
or without HIV coinfection, suggest that this is a new human T-cell
population involved in TB.
Future studies are then needed to better dissect this HLA-E-
restricted response and to precisely determine the relative impor-
tance of effector/protective versus immunoregulatory/pathogenic
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Peripheral blood was obtained from 24 adults with TB disease
(15 men, 9 women, age range 42–61 years) from the Diparti-
mento di Medicina Clinica e delle Patologie Emergenti, University
Hospital, Palermo, 15 LTBI subjects (10 men, 5 women, age range
38–59 years), and 10 tuberculin-negative healthy subjects (7 men
and 3 women, age range 40–57 years).
TB-infected patients had clinical and radiological findings con-
sistent with active pulmonary TB [48]. Diagnosis was confirmed
by bacteriological isolation ofM. tuberculosis in 14 patients. Other
patients were classified as having highly probable pulmonary TB
on the basis of clinical and radiological features that were highly
suggestive of TB and unlikely to be caused by any other dis-
ease; the decision was made by the attending physician to initiate
anti-TB chemotherapy, which resulted in an appropriate response
to therapy. All patients were treated in accordance with Italian
guidelines and received therapy for 6 months. Treatment was suc-
cessful in all participants all of whom completed the full course of
anti-TB chemotherapy, as shown by the absence of any clinical or
radiographic evidence of recurrent disease and sterile mycobac-
terial cultures. Peripheral blood was collected before (TB0) and
4 (TB4) and 6 months after completion of chemotherapy (TB6).
None of the TB patients had been vaccinated with BCG, or were
being treated with steroid or other immunosuppressive or antitu-
bercular drugs at the time of their first sampling. Three patients
had evidence of HIV infection. Tuberculin (PPD) skin tests were
considered positive when the induration diameter was larger than
10mm at 72 h since injection of 5 U of PPD (Statens Seruminstitut,
Copenhagen, Denmark).
Individuals with LTBI were defined as healthy people with a
positive tuberculin (PPD) skin test and no symptoms and signs of
active TB [49]. However, because the response to QuantiFERON-
TB Gold test was found in 73% (11/15) of PPD-positive LTBI
subjects, only those 11 subjects positive to QuantiFERON TB Gold
test were considered as being latently infected and were included
in the study. All of the LTBI subjects were health-care workers,
and thus very likely to be close contacts of TB index cases. More-
over, none of the LTBI subjects included in this study had been
vaccinated with BCG.
Ethics statement
The studywas approved by the Ethical Committee of the University
Hospital, Palermo, where the patients were recruited. The study
was performed in accordance to the principles of the Helsinki
Declaration and those of the “Good Clinical Practices,” and all
individuals gave written informed consent to participate.
Peptide-HLA-E binding assays
Murine TAP2-deficient T-cell lymphoma RMA-S-cell line cotrans-
fected with human β2-microglobulin and HLA-E*01033 allele
(RMA-S/HLA-E, kindly provided by J. E. Coligan, Laboratory of
Immunogenetics, NIAID, Rockville, MD, USA) was used in the
experiments. RMA-S/HLA-E cells were resuspended in complete
Roswell Park Memorial Institute medium at 1 × 106 cells/mL
and incubated either alone or in the presence of the synthetic
peptides (200 μM). The M. tuberculosis derived peptides used
in these experiments are derived from [13] and are listed in
Table 1. The canonical VMAPRTLIL peptide sequence, identical
to that present in most HLA-C alleles [33], was used as a positive
control in binding experiments.
After an overnight incubation at 37°C, cells were washed
with PBS to remove free peptides. Next, HLA-E surface expres-
sion was monitored after staining with the anti-HLA class I mAb
A6.136 (IgM, produced in our laboratory) followed by appropriate
PE-conjugated goat antimouse Ab.
CD8 T-cell proliferation induced by M. tuberculosis
peptides
PBMCs were labelled with CFSE (5 mM, Molecular Probes,
Eugene, OR, USA) and 105 cells were stimulated with M. tuber-
culosis derived HLA-E-binding peptides at a concentration of
10 μg/mL in complete RPMI 1640 medium (Euroclone, Devon,
UK) supplemented with 10% heat-inactivated pooled human AB+
serum, 2 mM L-glutamine, 20 mM HEPES, 100 U/mL penicillin,
100 μg/mL streptomycin, and 5 × 10−5 M 2-mercaptoethanol
(complete medium) in the presence of 5 ng/mL IL-7 (Pepro-
tech, Rocky Hill, NJ, USA), as described in [13]. Positive (PHA,
1μg/mL; Life Technologies, Paisley, UK) and negative (medium
only) controls were included in each assay. On day 7 of culture,
cells were harvested, replicates (n = 6) pooled and stained using
CD3-PerCP, CD8-APC, and CD56-PE (BD Biosciences, San Jose´,
CA, USA) before acquisition on a FACSCalibur using CellQuest
Pro software (BD Biosciences).
To analyze proliferation, cells were gated on lymphocytes, fol-
lowed by gating on CD3+CD8+CD56− cells. The percentage of
proliferation was calculated using geometric means by subtract-
ing the geometric mean of all cells from the geometric mean of
the undivided population. Subsequently, the percentage was cal-
culated by the following: (delta geo mean of sample − delta geo
mean of negative control)/delta geo mean of maximal prolifera-
tion [13].
Isolation and culture of NK cells
NK cells from healthy donors were isolated using the Rosette Sep
method (Stem Cell Technologies, Vancouver, BC, Canada). Only
those populations displaying >95% of CD56+CD3− NK cells were
selected. Purified NK cells were then cultured on irradiated feeder
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cells in the presence of 2 μg/mL PHA and 100 U/mL IL-2 (Pro-
leukin, Novartis Pharma AG, Basel, Switzerland) to obtain, after
limiting dilution, clonal NK cells. Proliferating NK-cell clones were
selected on the basis of the expression of either CD94/NKG2A or
CD94/NKG2C receptors as determined by flow cytometric anal-
ysis with the Z270 mAb (IgG1, anti-NKG2A produced in our
laboratory) and the 1381 mAb (IgG2b, anti-NKG2C, R&D Sys-
tems, Minneapolis, MN, USA). To analyze the surface markers
of NK-cell clones, cells were incubated with mAbs followed by
PE-conjugated isotype-specific goat antimouse second reagents
(Southern Biotechnology Associates, Birmingham, AL, USA). Sam-
ples were analyzed on a FACSCalibur with the CellQuest program
(BD Biosciences).
NK-cell cytolytic activity
NK-cell clones were tested for cytolytic activity in a 4-h 51Cr-
release assay as described [50] in the presence or absence of anti-
CD94 mAb Y9 (IgM, 10μg/mL). Target cells used in these exper-
iments were RMA-S/HLA-E (described above) and the human
erythroleukemic cell line K562 transfected with HLA-E*0103
(K562/HLA-E, kindly provided by E. H. Weiss, Department of
Biology, Anthropology andHumanGenetics, Ludwig-Maximilians-
Universita¨t, Munich, Germany) [51]. Target-cell lines were previ-
ously incubated overnight at 37°C, either alone or in the presence
of the synthetic peptides (200μM). Peptides were kept throughout
the assay to assure higher levels of HLA-E expression. E:T ratios
used in experiments are indicated in figures.
Generation of CD8 T-cell lines and functional assays
PBMCs from TB patients were cultured with 10 μg/mL of M.
tuberculosis derived peptides at 3 × 106 cells/well in complete
medium and human recombinant IL-2 (40 U/mL) [52]. Every
3 days, the culture was refreshed by medium plus IL-2 (40 U/mL).
After 15 days, cultures were restimulated weekly with an equal
number of peptide-pulsed irradiated (120 Gy from a Caesium
source) K562/HLA-E cells, in the presence of 40 U/mL IL-2 and 15
ng/mL IL-15. After four to five cycles of restimulation, the enriched
population contained >80% CD8+ T cells (also see Table 2). Cells
were restimulated weekly as described earlier.
CD8 T-cell lines were analyzed in detail by flow cytometry.
Fluorochrome-conjugated antibodies used for staining included
CD3 (HIT3a or SK-7, BD Biosciences), CD8 (RPA-TB or SK1, BD
Biosciences), CD45 (2D1, BD Biosciences), CD56 (B159, BD Bio-
sciences), CD94 (HP-3D9, BD Biosciences), CD16 (3GB, BD Bio-
sciences), TCR αβ (WT31, BD Biosciences), NKG2A (134111, R&D
Systems), NKG2C (1381, R&D Systems), Granzyme B (GB11, BD
Biosciences), rabbit anti-human granulysin (a kind gift of Dr. A.
Krensky, Stanford, CA, USA) in combination with goat-anti-rabbit
FITC (BD Biosciences), TRAIL (RIK-2, eBioscience), perforin (dG9,
eBiosciences), or isotype-control mAbs.
Samples were acquired on a FACSCanto and analyzed using
FACSDiva software (BD Biosciences). Scoring was based on the
percentage of cells that expressed the particular marker, andmark-
ers expressed by 10% of the cells, or more, were considered posi-
tive. The gating strategy is shown in Supporting Information Fig-
ure 6.
For functional assays, cells were maintained for 1 week with-
out restimulation (i.e. only with IL-2 and IL-15) before assays
were done. CD8+ T cells (5 × 104) were incubated with K562 or
K562/HLA-E cells in the presence or absence of synthetic peptides.
After 24 h, the supernatants were collected and stored at −70°C
until testing. Cytokine levels (TNF-α, IFN-γ, TGF-β, IL-2, IL-4,
IL-5, IL-10, IL-13, IL17, and IL-22) were assessed by ELISA (R&D
Systems). In some experiments, cocultures were carried out in
the presence of blocking mAbs to HLA-E (3D12, BioLegend,
San Diego, CA, USA), HLA-A/B/C (G46-2.6, BD Biosciences),
anti-HLA Class I monomorphic (MEM-147, from Prof. V. Horejsi,
Institute of Molecular Genetics, Prague, Czech republic), anti-CD3
(blocking, MEM-57 from Prof. V. Horejsi), anti-TCR αβ (WT31,
BD Biosciences), CD8 (RPA-TB, BD Biosciences), NKG2D (1D11,
eBioscience, San Diego, CA), NKG2C (1381, R&D Systems), CD94
(HP-3D9, BD Biosciences), or isotype-matched mAbs at 10 μg/mL
final concentrations.
The cytotoxic activity of CD8 T-cell lines was assessed fol-
lowing 6-h incubation with unpulsed or peptide-pulsed K562 or
K562/HLA-E target cells at an E:T ratio of 10:1. Evaluation of
dead cells was performed by flow cytometry after incubation with
annexin-V-FLUOS staining kit (Roche Diagnostics, Milan, Italy) for
the detection and quantification of apoptosis and differentiation
from necrosis at single cell level, based on Annexin-V-labeling. In
some experiments, cytotoxic assay was carried out in the pres-
ence mAbs to FasL (CD95L, 2C101, Vinci Biochem, Firenze, Italy),
TNF-α (Infliximab, a gift of Prof. G. Triolo, Dipartimento
Biomedico di Medicina Interna e Specialistica, Universita` di
Palermo, Palermo, Italy), or TRAIL receptors 1 (DR4) and 2
(DR5), both provided by Dr. H. Walczak (Tumor Immunology
Unit, Division of Medicine, Imperial College, London, UK). To
inhibit perforin-mediated cytotoxicity CD8 T-cell lines were incu-
bated with CMA (Sigma, St. Louis, MO, 15 nM final concentration)
for 30 min at 37°C prior to coculture, without further washing.
Pretreatment of CD8 T-cell lines with CMA at the concentration
used in this study did not have any cytotoxic effect.
Cytotoxicity of M. tuberculosis cells and assessment of
viability of M. tuberculosis
THP-1-, K562-, and K562/HLA-E-cell lines were infected for 24 h
at 37°C, 5% CO2 with single-cell suspensions of M. tuberculosis
H37Rv strain at a multiplicity of infection of 10. The infection was
carried out in the absence of antibiotics, and post treatment, cells
were washed with PBS to eliminate extracellular bacteria. Via-
bility of infected cells was determined by trypan blue exclusion.
Infected or uninfected THP-1-cell line and K562/HLA-E cells were
extensively washed and added to peptide-specific CD8 T-cell lines
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at an E:T ratio of 10:1. After 6 h of coculture, cytotoxicity of tar-
get cells was assessed by flow cytometry, as previously described,
after incubation with annexin-V-FLUOS staining kit (Roche Diag-
nostics).
M. tuberculosis infected THP-1-, K562-, and K562/HLA-E-cell
lines were incubated with peptide-specific CD8 T-cell lines for
20 h at 37°C as described above, washed three times to eliminate
bacteria that were not cell associated, lysed with 0.1% saponin,
and sonicated for 20 s. Serial tenfold dilutions were made in 7H9
broth and plated on 7H10 agar plates. Plates were sealed in plastic,
kept at 37°C, and the number of colonies (CFUs) was counted after
14–21 days [53].
A human HLA-A*0201-restricted CD8 T-cell clone specific for
M. tuberculosis Ag 16-kDa120-128 [52] was used as a positive con-
trol.
Intracellular cytokine staining
PBMCs (106/mL) were stimulated with peptides in the pres-
ence of monensin for 6 h at 37°C in 5% CO2. The cells were
harvested, washed, and stained with anti-CD8 mAb (RPA-TB, BD
Biosciences) in incubation buffer (PBS-1% FCS-0.1% Na azide) for
30 min at 4°C. The cells were washed twice in PBS-1% FCS and
fixed with PBS-4% paraformaldehyde overnight at 4°C. Fixation
was followed by permeabilization with 1% PBS, 0.3% FCS, 0.1%
saponin, and Na azide for 15 min at 4°C. Staining of intracellu-
lar cytokines was performed by incubation of fixed permeabilized
cells with anti-IFN-γ (25723.11, BD Biosciences), anti-IL-2 (MQ1-
17H12, BD Biosciences), anti-TNF-α (MAb11, BD Biosciences),
anti-IL10 (BT-10, eBioscience), anti-IL-17A (eBio64DEC17, eBio-
science), anti-IL-4 (BD Biosciences, 3010.211), anti-IL13 (Biole-
gend, JES10-5A2) mAbs or isotype-matched control mAbs. Cells
were acquired and analyzed by FACS as described above. Analysis
was performed on a minimum of 100 000 CD8 events acquired for
each sample.
Negative controls were obtained with CD8 T-cell lines incu-
bated with medium, in the absence of any stimulant. Cut-off val-
ues for a positive response were predetermined to be in excess
of 0.01% responsive cells [31, 37]. Results below this value were
considered negative and set to zero [31, 37].
Tetramer staining
Tetramer staining was carried out as described in detail previously
[31, 37, 54]. PBMCs (106/mL) were incubated in U-bottom 96-
well plates, washed twice in PBS containing 1% FCS (Sigma),
and stained for 30 min at 4°C with PE-labeled tetramers (5 μL
each) prepared as previously described [31, 37, 54]; they were
washed and subsequently stainedwith FITC-labeled anti-CD8mAb
(RPA-TB, BD Biosciences) and analyzed by flow cytometry on a
FACSCanto. Data were analyzed with the use of FACSDiva (BD
Biosciences). Viable lymphocytes were gated by forward and side
scatter and the analysis was performed on 100 000 CD8 events
acquired for each sample. A cutoff of 0.01% was used as described
previously [31, 37]; values below this were set to zero.
Ab production in vitro
CD8 T-cell help in Ab production was studied according to [55].
HLA-E-restricted CD8 T-cell lines or CD8 T cells isolated from
the PBMCs of healthy donors were cocultured with sorted ton-
sillar B cells in 96-well plates at 105 cells/well each of T and
B cells, in RPMI 1640 medium supplemented with 10% heat-
inactivated FCS, 2 mM L-glutamine, 20 nM HEPES, and 100 U/mL
penicillin/streptomycin. Ten days later IgG and IgM levels in the
culture supernatants were determined by ELISA.
Statistics
Nonparametric Mann–Whitney U test was used to determine sta-
tistical differences in the distribution of the results. Values of
p < 0.05 were considered significant. Data were analyzed using
statistical software SYSTAT 11 (Systat Software).
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